CTNNB1 and plasma cell myeloma: The decreased osteogenic potential of MSC from the bone marrow of myeloma patients has been described by different groups and appears to be associated with both increased expression of inflammatory cytokines [25] and inhibition of the canonical Wnt/beta-Catenin pathway required for osteoblastic differentiation [26].